Cost utility Analysis of Adult Patients with Severe Aplastic Anemia Based on Single-center Cohort Study

Abstract

Abstract Objective The purpose of this study is to objectively evaluate the efficacy of cyclosporine A + ALG and cyclosporine A + TPO-RA in the treatment of SAA patients, and to provide scientific data support for maximizing the therapeutic benefit of SAA patients. Method Cost-utility analysis was used to compare the quality of life adjusted years and total cost of the two schemes. The patient utility value was obtained from EQ-5D-3L and Japanese TTO conversion, and the total cost of treatment was obtained from electronic questionnaire survey and medical information data. Results A total of 26 adult patients were included in the study, including 17 with cyclosporine A + ALG and 9 with cyclosporine A + TPO-RA. In terms of QALY, patients with cyclosporine A + ALG regimen had higher intuitive feelings than those with cyclosporine A + TPO-RA regimen from admission to 6 months of follow-up, and the quality of life of patients with the former regimen was also significantly higher than that of the latter, with a difference of 0. 08 QALY (P < 0.01). In terms of total cost, the total cost of the former was twice that of the latter.Each QALY obtained by the two regimens was 687,000 yuan and 450,000 yuan, respectively.Compared with the cyclosporine A + TPO-RA regimen, the total cost of each QALY increased by the cyclosporine A + ALG regimen was 1.51 million yuan. Conclusion On the premise of ensuring the effectiveness of diagnosis and treatment, CsA + TPO-RA can be used as a good treatment option, which can reduce the economic pressure of SAA patients, reduce the burden of disease, reduce the pressure of medical insurance funds, and achieve multi-benefits.